Vanda Pharmaceuticals (VNDA) Reports In-Line Q2 EPS
Tweet
Share
E-mailGet Alerts VNDA Hot Sheet
Price: $5.16 --0%
Revenue Growth %: +24.1%
Financial Fact:
Product sales: 38.48M
Today's EPS Names:
OCCI, ALZN, ASPU, More
Revenue Growth %: +24.1%
Financial Fact:
Product sales: 38.48M
Today's EPS Names:
OCCI, ALZN, ASPU, More
Join SI Premium – FREE
Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q2 EPS of ($0.05), in-line with the analyst estimate of ($0.05). Revenue for the quarter came in at $7.4 million versus the consensus estimate of $8.07 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- MillerKnoll, Inc. (MLKN) Tops Q1 EPS by 18c ; Offers Guidance
- Lennar Corp. (LEN) Misses Q3 EPS by 10c
- Forgent Power Solutions, Inc. (FPS) Tops Q2 EPS by 1c, Beats on Revenue; Offers FY27 Guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
